Grik4 Antibody
| Code | Size | Price |
|---|
| PSI-4391-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4391-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
Grik4 Antibody: KA1, EAA1, GRIK, GluK4, Glutamate receptor ionotropic, kainate 4, Excitatory amino acid receptor 1
Application Note:
Grik4 antibody can be used for detection of Grik4 by Western blot at 0.5 - 2 μg/mL. Despite its predicted molecular weight, Grik4 often migrates at a lower molecular weight in SDS-PAGE. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Background:
Grik4 Antibody: Grik4 codes for the KA1 subunit of kainate-type ionotropic glutamate receptors which are critical regulators of network activity that act by modifying neuronal excitability, directly and indirectly, through GABAergic interneurons. Five subunits can assemble to form kainate receptors (KARs): GluR5 (coded by Grik1), GluR6 (coded by Grik2), and GluR7 (coded by Grik3) are the low-affinity subunits, and KA1 and KA2 are the high-affinity subunits. In the adult brain, KARs are located pre- and postsynaptically on pyramidal cells and on interneurons. Kainate receptors on GABA-containing interneurons enhance GABA release and thereby downregulate glutamatergic signaling. KARs have been implicated in numerous psychiatric disorders. Case control studies show significant association of Grik4 with both schizophrenia and bipolar disorder.
Background References:
- Tanaka K. Functions of glutamate transporters in the brain. Neurosci. Res.2000; 37:15-9.
- Pinheiro P and Mulle C. Kainate receptors. Cell Tissue Res.2006; 326:457-82.
- Mayer ML. GRIK4 and the Kainate Receptor. Am. J. Psychiatry2007; 164:1148.
- Pickard BS, Malloy MP, Christoforou A, et al. Cytogenetic and genetic evidence supports a role for the kainate-type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol. Psychiatry2006; 11:847-57.
Buffer:
Grik4 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Grik4 antibody was raised against a 18 amino acid synthetic peptide near the carboxy terminus of the mouse Grik4.
The immunogen is located within the last 50 amino acids of Grik4.
The immunogen is located within the last 50 amino acids of Grik4.
NCBI Gene ID #:
110637
NCBI Official Name:
glutamate receptor, ionotropic, kainate 4
NCBI Official Symbol:
GRIK4
NCBI Organism:
mus musculus
Physical State:
Liquid
Protein Accession #:
NP_780690
Protein GI Number:
304766513
Purification:
Grik4 Antibody is affinity chromatography purified via peptide column.
Research Area:
Neuroscience
Swissprot #:
Q8BMF5
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | Grik4 Peptide | PSI-4391P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|